CLINICAL_TRIALS
trial_result
· 2017-03-10
Clinical Trial Update: Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022) [Phase 3]
Summary
Phase 3 trial evaluating re-injection of NX-1207 for benign prostatic hyperplasia has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nymox Corporation | Conditions: Benign Prostatic Hyperplasia, BPH | Phase 3 | Status: COMPLETED